Cellworks Research India, the Bangalore-based research and development (R&D) wing of Cellworks Group Inc (California-headquartered company), has assisted Chennai-based Orchid Chemicals and Pharmaceuticals by providing system biology technology in carrying out ongoing New Chemical Entity (NCE) research programme.
[This article was published in the January 2008 issue of the eHEALTH Magazine (https://www.ehealthonline.org) ]
IBM is targeting multi-billion dollar health business opportunities in India. The company has plans to tap opportunities worth $1 billion each in the Indian pharmaceuticals and health service segments over the next 3-4 years.
IBM is targeting multi-billion dollar health business opportunities in India. The company has plans to tap opportunities worth $1 billion each in the Indian pharmaceuticals and health service segments over the next 3-4 years.
IBM is targeting multi-billion dollar health business opportunities in India. The company has plans to tap opportunities worth $1 billion each in the Indian pharmaceuticals and health service segments over the next 3-4 years.
IBM is targeting multi-billion dollar health business opportunities in India. The company has plans to tap opportunities worth $1 billion each in the Indian pharmaceuticals and health service segments over the next 3-4 years.
[This article was published in the December 2007 issue of the eHEALTH Magazine (https://www.ehealthonline.org)]
News Review
Ranbaxy Laboratories may dilute up to 60% stake in its new research company, which will be formed by hiving off its R&D unit into a separate entity in 2008.
Cellworks Group Inc, a California based company, has set up its R&D centre in Bangalore, India. Cellworks Research India Limited (CRIL), the R&D centre of Cellworks, would develop and provide technology based solutions that hasten drug discovery research and development.
The LORENZ Life Sciences Group announced recently that Orchid Chemicals & Pharmaceuticals, located in Chennai, India has chosen docuBridge as its eCTD Publishing and Management solution.
[This article was published in the November 2007 issue of the eHEALTH Magazine (https://www.ehealthonline.org)]
Success parameters of pharma companies are typically attributed to their R&D productivity and �time-to-market� of productised innovations.
Private Equity (PE) investments in the domestic healthcare and pharma industry have touched around $400 million during the first nine months of the year. This trend is set to accelerate as companies go for overseas acquisitions, hive off their R&D units, and Foreign Currency Convertible Bonds (FCCB) lose their sheen.
[This article was published in the June 2007 issue of the eHEALTH Magazine (https://www.ehealthonline.org)]
When patients are more involved in their own healthcare, including the management of their personal health data, they become active participants in their healthcare and become more responsible.
